Zimvie INC 8-K filings

ARCHIMED has completed its acquisition of ZimVie Inc., taking the global dental implant leader private at $19.00 per share.

ZimVie Inc. stockholders have overwhelmingly approved the acquisition of the company by an affiliate of ARCHIMED, paving the way for the merger to close on October 20, 2025.

ZimVie Inc. has filed supplemental disclosures to its merger proxy statement in response to stockholder litigation alleging material omissions, aiming to avoid delays in its acquisition by Zamboni Parent Inc.

ZimVie Inc. announced its second quarter 2025 financial results, showing improved profitability metrics, alongside the definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash, expected to close by year-end 2025.

ZimVie Inc., a global life sciences leader in the dental implant market, has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a significant premium for its stockholders.

ZimVie Inc. held its annual shareholder meeting on May 7, 2025, where shareholders elected a director, ratified the appointment of PricewaterhouseCoopers LLP as the company's auditor, and approved executive compensation on an advisory basis.

ZimVie Inc. reported its Q1 2025 financial results, highlighting a decrease in net sales but improvements in net loss and adjusted EBITDA margins, alongside full-year 2025 financial guidance.

David King, Non-Executive Chair of ZimVie Inc.'s Board, will not seek reelection, leading to Vafa Jamali's appointment as Chairman and Vinit Asar as Lead Independent Director, effective May 7, 2025.

ZimVie Inc. reported its fourth quarter and full year 2024 financial results, highlighting a transformational year focused on becoming a pure-play dental company and improving its financial profile.

ZimVie Inc. announced its third quarter 2024 financial results, showing improvements in net loss and adjusted EBITDA, and provided updated full-year 2024 financial guidance.

ZimVie reported a net loss for the second quarter of 2024, but reaffirmed its full-year financial guidance.

ZimVie Inc. held its annual shareholder meeting on May 15, 2024, where shareholders elected directors, ratified the appointment of the auditor, and approved executive compensation.

ZimVie reported a net loss of $11.5 million for Q1 2024, but saw improvements in adjusted EBITDA and completed the sale of its spine business, paying down $275 million in debt.

ZimVie Inc. has finalized the sale of its spine business to H.I.G. Capital for $315 million in cash and a $60 million promissory note, and has released pro forma financial information reflecting the transaction.

ZimVie has finalized the sale of its Spine business to an affiliate of H.I.G. Capital for $375 million, marking a strategic shift to focus on its dental business.

ZimVie's fourth quarter and full year 2023 results show a mixed performance with a focus on the upcoming sale of its spine business and a transition to a pure-play dental company.